|
For developing, manufacturing and marketing any type of medication
the formal or official approval from the authorized government
agency called the Food and Drugs Administration – FDA is mandatory
in any developed countries across the world. This agency intensively
tests, examines and undertakes authentic clinical trials of the
intended medicine in terms of the efficacy, pharmacology, working
and treatment, side effects and drug interactions etc of the
medicine in question and only on the basis of their thorough results
they sanction necessary approval with mandatory guidelines for its
commercial aspects. No drugs can ever be manufactured or sold in
public without such clearance from the FDA, especially in the United
States.
Indocin, too has passed through such rigorous trials and related
formalities and finally got approved by the U.S. FDA for
manufacturing and marketing the product within the country by Merck
& Co Inc of the United States. Indocin is the non-steroidal
anti-inflammatory drug – NSAID and has been reported showing
antipyretic and analgesic properties. The mode of action of Indocin
is not because of pituitary-adrenal stimulation and it is the
powerful or effective inhibitor of prostaglandin synthesis in vitro.
The concentrations reached during the Indocin treatment have shown
to have the remarkable effect in vivo also. Prostaglandin sensitizes
afferent nerves and enables the action of bradykinin including pain.
Prostaglandin is believed to be involved as one of the intimidators
of inflammation.
Indocin is directed for use the lowest effective dose for the
shortest duration consistent depending on the individual patient’s
condition. The drug has been found effective in active stages of:
moderate to sever rheumatoid arthritis including acute flare of
chronic condition, ankylosing spondylitis, osteoarthritis, acute
painful shoulder and acute gouty arthritis.
|
